GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q3 FY20 results · Oct–Dec 2019
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹778.59 crore and net loss of ₹661.16 crore for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 778.59 | — | — | 882.02 | −11.7% |
| Other income | 16.50 | — | — | 15.88 | +3.9% |
| Total income | 795.09 | — | — | 897.90 | −11.5% |
| Profit before tax | (634.32) | — | — | 587.41 | Turned loss |
| Net profit for the period | (661.16) | — | — | 502.75 | Turned loss |
| EPS, basic (₹) | (39.03) | — | — | 29.68 | Turned loss |
| Net margin (%) | -84.9 | — | 57.0 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 778.68 | 825.35 | −5.7% | 882.10 | −11.7% |
| Other income | 16.25 | 16.42 | −1.0% | 15.61 | +4.1% |
| Total income | 794.93 | 841.77 | −5.6% | 897.71 | −11.4% |
| Profit before tax | (617.31) | 169.78 | Turned loss | 587.37 | Turned loss |
| Net profit for the period | (644.14) | 112.97 | Turned loss | 502.79 | Turned loss |
| EPS, basic (₹) | (38.02) | 6.67 | Turned loss | 29.68 | Turned loss |
| Net margin (%) | -82.7 | 13.7 | 57.0 |
Consolidated
- Filed with BSE
- 04 Feb 2020, 12:02 IST
- Board meeting
- 03 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Feb 2020, 12:02 IST
- Board meeting
- 03 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE